Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events.

Machiko KawahiraShuji KanmuraKeiko MizunoKentaro MachidaTakao OhtsukaMasami SatoHideki EnokidaMasaru YamashitaTakuro KanekuraShiho ArimaNorifumi NakamuraTsuyoshi SugiuraKoji YoshimotoHiroaki KobayashiKenji IshitsukaShinsuke SuzukiShinichi UenoAkio Ido

Published in: PloS one (2022)

Patients with initial multisystemic irAEs and irAEs of grade ≥2 were more likely to experience relapse or develop new grade ≥2 irAEs after ICI resumption.

Keyphrases

high intensity
early onset
stem cells
drug induced
free survival
bone marrow
mesenchymal stem cells
cell therapy